AHA 2019 Discussion: The DAPA-HF Study

Published: 22 Nov 2019

  • Views:

    Views Icon 182
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating


Dr Harriette Van Spall (McMaster University, Ontario, CA) & Prof John McMurray (Glasgow University Hospital, UK) discuss the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF) - Sub-studies and sensitivity analyses.

The aim of this study was to assess the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction

Filmed on site at AHA 2019 by Radcliffe Cardiology.

Videographer: Tom Green & Dominic Woodruff